v3.26.1
Segment Information - Schedule of the Reportable Segment and Includes the Reconciliation to Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Revenue $ 218,375   $ 150,042   $ 409,578 $ 271,505
Cost of revenue (excluding amortization and depreciation) 13,564   13,448   28,289 23,237
Research and development expense recognized 46,227   49,541   98,904 94,326
Other research and development [1] 3,073   3,229   17,058 7,198
General and administrative expense (excluding share-based compensation expense) 24,615   13,234   46,639 24,884
Selling and marketing expense (excluding stock-based compensation expense) 164,113   99,376   310,550 191,664
Stock-based compensation expense 27,148   24,611   50,586 47,919
Gain in fair value of contingent consideration (1,496)   (8,102)   (906) (6,590)
Interest expense, net [2] 1,540   1,834   2,725 4,265
Other segment items [3] 1,717   11,014   3,289 12,586
Segment net loss (51,314)   (47,973)   (115,856) (107,386)
Reconciliation of net loss            
Adjustments and reconciling items 0   0   0 0
Net loss (51,314) $ (64,542) (47,973) $ (59,413) (115,856) (107,386)
Solriamfetol            
Segment Reporting [Line Items]            
Research and development expense recognized 13,397   10,770   24,628 22,576
AXS-05            
Segment Reporting [Line Items]            
Research and development expense recognized 11,491   14,564   22,395 29,041
AXS-07            
Segment Reporting [Line Items]            
Research and development expense recognized 4,584   6,075   10,054 10,554
AXS-12            
Segment Reporting [Line Items]            
Research and development expense recognized 2,399   1,737   3,887 4,146
AXS-14            
Segment Reporting [Line Items]            
Research and development expense recognized $ 3,544   $ 6,225   $ 6,240 $ 7,411
[1] Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, costs related to asset acquisitions, and other unallocated costs.
[2] Interest expense, net of $1,540 for the three months ended June 30, 2026 comprises (i) consolidated interest expense of $3,200 and (ii) consolidated interest income of $1,660. Interest expense, net of $2,725 for the six months ended June 30, 2026 comprises (i) consolidated interest expense of $6,292 and (ii) consolidated interest income of $3,567. Interest expense, net of $1,834 for the three months ended June 30, 2025 comprises (i) consolidated interest expense of $4,086 and (ii) consolidated interest income of $2,252. Interest expense, net of $4,265 for the six months ended June 30, 2025 comprises (i) consolidated interest expense of $9,344 and (ii) consolidated interest income of $5,079.
[3] Other segment items included in Segment net loss include intangible asset amortization, loss on debt extinguishment, and other miscellaneous items.